Press Releases and Publications. 6.1 The Parties shall jointly agree to the content and timing of all external communications with respect to this Collaboration Agreement (including, without limitation, press releases, Q&As, and the content and wording for of any listing of any Joint Global Study required to be listed on a public database or other public registry such as wxx.xxxxxxxxxxxxxx.xxx). For clarity, if either Party terminates this Collaboration Agreement pursuant to Section 11 of the License Agreement, the Parties shall mutually agree upon any external communication related to such termination, which shall not include the rationale for such termination unless (and to the extent) mutually agreed by the Parties; provided that either Party shall be permitted to publicly disclose information that such Party determines in good faith is necessary to be disclosed to comply with Applicable Law or the rules or regulations of any securities exchange on which such Party’s stock may be listed, or pursuant to an order of a court or governmental entity.
6.2 Allist and AxxxXxxx agree to collaborate to publicly disclose, publish or present; (1) top-line result from each Joint Global Study, limited if possible to avoid jeopardizing the future publication of the Study Data at a scientific conference or in a scientific journal, solely for the purpose of disclosing, as soon as reasonably practicable, the safety or efficacy results and conclusions that are material to any Party under applicable securities laws, and (2) the conclusions and outcomes (the “Results”) of each Joint Global Study at a scientific conference as soon as reasonably practicable following the completion of such Joint Global Study, subject in the case of (2) to the following terms and conditions. The Party proposing to disclose, publish or present the Results shall deliver to each other Party a copy of the proposed disclosure, publication, or presentation at least [***] ([***]) business days before submission to a Third Party.
Press Releases and Publications. (a) The Parties shall jointly agree (such agreement not to be unreasonably withheld by either Party) to the content and timing of all public communications with respect to this Agreement (including without limitation press release(s) pertaining to execution of this Agreement (if any) and other press releases), Q&As, and the content of, and wording for, any listing of the Combined Therapy Clinical Trials required to be listed on a public database or other public registry (such as wxx.xxxxxxxxxxxxxx.xxx). For clarity, if either Party terminates this Agreement pursuant to Section 11.4, the Parties shall mutually agree upon any external communication related to such termination, which shall not include the rationale for such termination unless (and to the extent) mutually agreed by the Parties; provided that either Party shall be permitted to publicly disclose information that such Party determines in good faith is necessary to be disclosed to comply with Applicable Law or the rules or regulations of any securities exchange on which such Party’s stock may be listed, or pursuant to an order of a court or governmental entity.
(b) Olema shall have the exclusive right to publicly disclose, publish or present (i) top-line results from the Combined Therapy Clinical Trials, limited [***], solely for the purpose of disclosing, as soon as reasonably practicable, the safety or efficacy results and conclusions that are material to either Party under applicable securities laws, and (ii) the conclusions and outcomes of the Combined Therapy Clinical Trials (the “Results”), as set forth in the Final Study Report, at a scientific conference as soon as reasonably practicable following the completion of such Combined Therapy Clinical Trials, subject in the case of (ii) to the following terms and conditions. Olema shall deliver to Novartis a copy of the proposed disclosure, publication or presentation at least [***] before submission to a Third Party. Novartis shall determine whether any of its Confidential Information that is contained in such proposed disclosure, publication or presentation should be modified or deleted, and whether to file a patent application on any Novartis Study Invention disclosed therein. The disclosure, publication or presentation shall be delayed for an additional [***] (i.e., a total [***] from the initial proposal) if Novartis reasonably requests such extension to allow time for the preparation and filing of relevant patent applications directed to a...
Press Releases and Publications. 12.1 On or immediately after the Effective Date, Syndax and Merck will issue a press release in the form attached hereto as Schedule 12.1.
12.2 To the extent required by Applicable Law, Syndax will register the Study with the Clinical Trials Registry located at xxx.xxxxxxxxxxxxxx.xxx. Syndax is committed to timely publication of the results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study. The publication of the results of the Study will be in accordance with the Protocol.
12.3 Each Party shall use reasonable efforts to publish or present scientific papers dealing with the Study in accordance with accepted scientific practice. Each Party may issue a press release related to any scientific presentation or publication regarding the Study in a form mutually agreed to by the Parties.
12.4 The Parties agree that prior to submission of the results of the Study for publication or presentation or any other dissemination of results including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to be published or presented according to the following procedure:
(i) At least *** prior to submission for publication of any paper, letter or any other publication, or *** prior to submission for presentation of any abstract, poster, talk or any other presentation, the publishing Party shall provide to the other Party the full details of the proposed publication or presentation in an electronic version (cd-rom or email attachment). Upon written request from the other Party, the publishing Party agrees not to submit data for publication/presentation for an additional *** in order to allow for actions to be taken to preserve rights for patent protection.
(ii) The publishing Party shall give reasonable consideration to any request by the other Party made within the periods mentioned in clause (i) above to modify the publication and the Parties shall work in good faith and in a timely manner to resolve any issue regarding the content for publication.
(iii) The publishing Party shall remove all Confidential Information of the other Party before finalizing the publication.
12.5 Syndax agrees to identify Merck and acknowledge Merck’s support in any press release and any other publication or presentation of the results of the Study.
Press Releases and Publications. (a) The Parties shall jointly agree (which agreement shall not be unreasonably withheld or delayed) to the content and timing of all external communications with respect to this Agreement (including, without limitation, an initial press release (the content of which is attached hereto as Exhibit B), subsequent press releases, Q&As, and the content and wording for of any listing of the Combined Therapy Study required to be listed on a public database or other public registry such as wxx.xxxxxxxxxxxxxx.xxx). The Parties have agreed on the initial press release, having the content as set forth in Exhibit B, which will be issued at a time agreed by the Parties, but in any event no later than five (5) Business Days after the Effective Date (unless the Parties agree otherwise in writing). Notwithstanding the foregoing, information contained in external communications previously approved by the Parties may be included in subsequent external communications by either Party without review by, or the necessity to obtain prior approval from, the other Party. For clarity, if either Party terminates this Agreement pursuant to Section 12.4, the Parties shall mutually agree upon any external communication related to such termination, [*]. Notwithstanding the foregoing in this Section 9.5(a) or anything to the contrary in this Agreement, each Party shall be permitted to publicly disclose information that such Party determines in good faith is necessary to be disclosed to comply with Applicable Law or the rules or regulations of any securities exchange on which such Party’s stock may be listed, or pursuant to an order of a court or governmental entity.
(b) BMS will review, to the extent it has the right to do so under the Ono-BMS Agreement, and otherwise will use reasonable efforts to review Ono’s press releases, and shall permit Compugen to review any such press releases reviewed by BMS, regarding the Combined Therapy Study prior to publication to confirm that the subject matter of any such press releases by Ono is not more extensive than, and is otherwise consistent with, that which may have been released by Compugen and BMS under Section 9.5(a); provided that Ono shall be permitted to publicly disclose information disclosed to Ono in accordance with Section 9.4 to the extent necessary to comply with Applicable Law or the rules or regulations of any securities exchange on which Ono’s stock may be listed, or pursuant to an order of a court or governmental entity.
(c) Compu...
Press Releases and Publications. Subject to Sections 9.2.1 and 9.2.2, the Parties will mutually agree on the content and timing of any press release with respect to this Agreement or the Study.
Press Releases and Publications. 12.1 Neither Party shall publicly disclose the terms of this Agreement without the prior written consent of the other Party, provided that Vaccinex may disclose the terms on a need to know basis in connection with the Study to maintain their compliance to the obligations stated herein, as required, or as needed to comply with applicable laws, including any reporting obligations with the Securities and Exchange Commission or listing requirements of a securities exchange; and provided further that the Parties will issue a joint press release promptly after the Effective Date generally describing the clinical collaboration set forth hereunder (the “First Press Release”). Note: Reference to “Merck” in this document refers to the Group of Companies affiliated with Merck KGaA, Darmstadt, Germany.
12.2 To the extent required by Applicable Law or Vaccinex’s policies, Vaccinex will register the Study with the Clinical Trials Registry located at xxx.xxxxxxxxxxxxxx.xxx and any other local clinical registry if locally legally required. Vaccinex is committed to timely publication of the final Study Results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study in accordance with Section 3.9 and the review process described in Section 12.
Press Releases and Publications. 12.1 No Party shall publicly disclose the terms of this Agreement without the prior written consent of each of the other Parties provided that a Party may disclose the terms on a need to know basis in connection with the Study to maintain its compliance to the obligations stated herein, as required, or as needed to comply with applicable laws, including any reporting obligations with the Securities and Exchange Commission. If the Parties agree to issue a press release, following a review by all Parties, at least five (5) days after the Effective Date, it shall only generally describe the clinical collaboration set forth hereunder. After the First Press Release, the Parties agree to seek prior written approval from each other for any press release regarding the collaboration under this Agreement, and a Party will provide the others with the draft press releases at least seven (7) Business Days prior to distribution. Notwithstanding the forgoing, in the event that a planned press release references (1) any Compound Combination, (2) any Class Combination, or (3) any Party’s Compound in connection with any Class Combination, which has not previously been published, any Party whose Compound(s) or Class Compound(s) are implicated shall have no less than fifteen (15) Business Days to review and provide comments and if requested by such Party, the press release should be delayed for sixty (60) days from the intended release date to permit the Party to prepare and file a patent application.
12.2 To the extent required by Applicable Law or Pfizer’s policies, Pfizer will register the Study with the Clinical Trials Registry located at xxx.xxxxxxxxxxxxxx.xxx and any other local clinical registry if locally legally required. Pfizer agrees to provide any proposed registration to Alliance and Checkmate for review at least ten (10) days prior to registering the Study. Pfizer is committed to timely publication of the final results of the Study following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study, in accordance with Section 3.8 and the review process described in Section 12.3. The publication of the final results of the Study will be in accordance with the Protocol.
12.3 It is the Parties intention that the seminal results of the Study be published jointly; however and in any case, any publication or presentation of one Party relating to Jointly Owned Inventions, Protocol, Sample Testing Results th...
Press Releases and Publications. Neither Party shall issue any press release, trade announcement or make any other public announcement or statement with regard to the transactions contemplated by this Agreement without the other Party’s prior written consent, which shall not be unreasonably withheld. Where consent is forthcoming, the Parties agree to consult with each other regarding the content of any such press release or other announcement. The aforementioned restriction shall not apply to announcements required by any Regulatory Authority, security exchanges or Governmental Entity under applicable Law, provided, that in such event the Parties shall coordinate the wording and NLS shall take into consideration any requests of Novartis. Each Party hereto acknowledges that NLS and Novartis shall have the right to disclose a brief summary of the transaction, including the amounts payable by NLS under this Agreement, in its official financial reports.
Press Releases and Publications. 12.1 Neither Party shall publicly disclose the terms of this Agreement without the prior written consent of the other Party, provided that Syndax may disclose the terms on a need to know basis in connection with the Study to maintain their compliance to the obligations stated herein, as required, or as needed to comply with applicable laws, including any reporting obligations with the Securities and Exchange Commission; and provided further that the Parties will issue a joint press release promptly after the Effective Date generally describing the clinical collaboration set forth hereunder (the “First Press Release”).
12.2 To the extent required by Applicable Law or Syndax’s policies, Syndax will register the Study with the Clinical Trials Registry located at xxx.xxxxxxxxxxxxxx.xxx and any other local clinical registry if locally legally required. Syndax is committed to timely publication of the final Study Results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study in accordance with Section 3.9 and the review process described in Section 12.3. The publication of the final Study results will be in accordance with the Protocol.
12.3 Any publication or presentation of one Party relating to the activities governed under this Agreement requires prior written approval of the other Party. This includes, but is not limited to, all medical publications in peer-reviewed journals and abstracts and presentations at scientific or medical congresses. Any proposed publication or presentation of either Party shall be consistent with the other Party’s scientific standards. This will be achieved by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing primary data manuscripts before any non-primary data (e.g. secondary analyses, case studies). Each publishing Party agrees to submit any proposed publication or presentation to the other Party as follows: To the Alliance: email address: *** To Syndax: email address: *** for review at least *** prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within *** of its receipt, the other Party shall advise the publishing Party, ...
Press Releases and Publications. 13.1 PRESS RELEASES The parties agree to issue a joint press release, in the form attached hereto as Exhibit F, upon the Effective Date. All other press releases and public announcements related to this Agreement shall be approved in advance in writing by the other party.
13.2 PUBLICATIONS The parties shall mutually agree upon publications and the publication strategy with respect to work undertaken by the parties relating to Product, and neither party shall publish any result or study generated or developed under this Agreement except upon review by the other party at least sixty (60) days prior to submission of an abstract or manuscript for publication.
